アテローム性動脈硬化症治療薬市場- 世界の産業規模、シェア、動向、機会、予測、診断別、治療別、投与経路別、エンドユーザー別、地域別、競合別、2020～2030年

アテローム性動脈硬化症治療薬の世界市場は、2024年に188億5,000万米ドルと評価され、2030年には228億4,000万米ドルに達すると予測され、予測期間中に3.21％の複合年間成長率（CAGR）で成長します。

アテローム性動脈硬化症は、脂肪プラークの蓄積による動脈の狭窄と硬化を特徴とする病態であり、世界的に重要な健康問題であり続けています。心臓病、脳卒中、その他の心血管合併症の主な原因であり、年間数百万人が死亡しています。アテローム性動脈硬化症治療薬市場は、この病態の有病率の増加に牽引され、大幅な成長を遂げています。

食生活の乱れ、運動不足、喫煙などの不健康な生活習慣は、世界の動脈硬化の罹患率上昇の主な要因であり、治療を必要とする多くの患者を引き起こしています。さらに、世界人口の高齢化はより高いリスクを抱えており、これがアテローム性動脈硬化症治療薬の需要を促進すると予想されています。医療技術と診断の進歩により、早期発見が可能になり、よりタイムリーな介入と治療が促進されています。また、公衆衛生キャンペーンや心血管系の健康に対する意識の高まりも、より多くの人々に治療を受けるよう促しています。

アテローム性動脈硬化症治療薬の世界市場は大きなチャンスをもたらす一方で、課題にも直面しています。動脈硬化の負担が増加する中、効果的な治療法の開発には継続的な技術革新と研究が不可欠です。個別化医療と標的治療は、患者の予後改善に有望です。しかし、薬価、患者の服薬アドヒアランス、競争の激化に関する課題は、必要としている人々が確実にアクセスできるようにするために対処しなければなりません。製薬企業、ヘルスケアプロバイダー、政策立案者の協力は、アテローム性動脈硬化症とその世界ヘルスへの影響に対抗するために不可欠です。

市場促進要因

動脈硬化の有病率の上昇

主な市場課題

競合の増加

主要市場動向

技術の進歩

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 世界のアテローム性動脈硬化症治療薬市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 診断別（足首上腕血圧比、ドップラー超音波、心エコー、心電図、血液検査、その他）
  • 治療別（薬物療法、手術、その他）
  • 投与経路別（経口、非経口、その他）
  • エンドユーザー別（病院・クリニック、外来診療センター、その他）
  • 地域別
  • 企業別（2024）
• 市場マップ

第6章 北米のアテローム性動脈硬化症治療薬市場展望

• 市場規模・予測
• 市場シェア・予測
• 北米：国別分析
  • 米国
  • カナダ
  • メキシコ

第7章 欧州のアテローム性動脈硬化症治療薬市場展望

• 市場規模・予測
• 市場シェア・予測
• 欧州：国別分析
  • ドイツ
  • 英国
  • イタリア
  • フランス
  • スペイン

第8章 アジア太平洋地域のアテローム性動脈硬化症治療薬市場展望

• 市場規模・予測
• 市場シェア・予測
• アジア太平洋地域：国別分析
  • 中国
  • インド
  • 日本
  • 韓国
  • オーストラリア

第9章 南米のアテローム性動脈硬化症治療薬市場展望

• 市場規模・予測
• 市場シェア・予測
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第10章 中東・アフリカのアテローム性動脈硬化症治療薬市場展望

• 市場規模・予測
• 市場シェア・予測
• 中東・アフリカ：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦

第11章 市場力学

• 促進要因
• 課題

第12章 市場動向と発展

• 合併と買収（ある場合）
• 製品の発売（ある場合）
• 最近の動向

第13章 ポーターのファイブフォース分析

• 業界内の競合
• 新規参入の可能性
• サプライヤーの力
• 顧客の力
• 代替品の脅威

第14章 競合情勢

• F. Hoffmann-La Roche Ltd
• Novartis AG
• Merck & Co. Inc.
• Pfizer Inc.
• Eli Lilly and Co.
• Sanofi S.A.
• AstraZeneca Plc
• Bayer AG
• Regeneron Pharmaceuticals Inc.
• GSK Plc

第15章 戦略的提言

第16章 調査会社について・免責事項

The Global Atherosclerosis Drugs Market was valued at USD 18.85 billion in 2024 and is projected to reach USD 22.84 billion by 2030, growing at a compound annual growth rate (CAGR) of 3.21% during the forecast period. Atherosclerosis, a condition characterized by the narrowing and hardening of arteries due to fatty plaque accumulation, continues to be a significant global health issue. It is a leading cause of heart disease, stroke, and other cardiovascular complications, resulting in millions of deaths annually. The market for atherosclerosis drugs has seen substantial growth, driven by the increasing prevalence of this condition.

Unhealthy lifestyle factors such as poor diet, physical inactivity, and smoking are major contributors to the rising incidence of atherosclerosis worldwide, leading to a large patient population in need of treatment. Furthermore, the aging global population is at higher risk, which is expected to drive demand for atherosclerosis medications. Advances in medical technology and diagnostics have enabled earlier detection, facilitating more timely interventions and treatments. Public health campaigns and increasing awareness about cardiovascular health have also encouraged more individuals to seek treatment.

While the Global Atherosclerosis Drugs Market presents significant opportunities, it also faces challenges. With the rising burden of atherosclerosis, ongoing innovation and research are critical to developing effective therapies. Personalized medicine and targeted treatments show promise in improving patient outcomes. However, challenges related to drug pricing, patient adherence, and growing competition must be addressed to ensure accessibility for those in need. The collaboration between pharmaceutical companies, healthcare providers, and policymakers will be essential to combating atherosclerosis and its impact on global health.

Key Market Drivers

Rising Prevalence of Atherosclerosis

Atherosclerosis, characterized by plaque buildup in arteries, is becoming more widespread worldwide. This condition significantly increases the risk of heart attacks, strokes, and other cardiovascular diseases, making it a global healthcare priority. As modern lifestyles contribute to obesity, hypertension, and high cholesterol, the need for effective treatments for atherosclerosis is intensifying. Diets high in saturated fats, trans fats, and processed foods, common in many regions, further exacerbate the risk factors. Additionally, atherosclerosis is more prevalent in older individuals, and as the global population ages, the incidence of this condition is expected to rise, further stressing healthcare systems. Tobacco use and diabetes are also major contributors to the increasing prevalence of atherosclerosis.

Recent research has uncovered cancer-like features in atherosclerosis, highlighting potential new treatment avenues. Studies supported by the National Institutes of Health (NIH) suggest that smooth muscle cells in arteries may take on characteristics similar to cancer cells, worsening the condition. This discovery opens the door for novel therapies, such as using anti-cancer drugs to target these tumor-like processes, offering hope for more effective treatments.

Key Market Challenges

Increasing Competition

The atherosclerosis drugs market is highly competitive, with numerous established pharmaceutical companies and emerging players vying for market share. Major pharmaceutical companies like Pfizer, AstraZeneca, and Merck have dominated the market for years, benefiting from blockbuster drugs such as Lipitor (atorvastatin) and Crestor (rosuvastatin). However, newer entrants are introducing innovative therapies and specialized drug formulations targeting different aspects of atherosclerosis treatment. These companies are focusing on niche areas such as LDL cholesterol reduction or inflammation to address unmet needs in the market.

The rise of biosimilars and generics has further intensified competition, as these cost-effective alternatives to branded drugs become more prevalent. Smaller companies or startups face challenges related to regulatory approvals, clinical trials, and securing adequate funding. The dominance of established market leaders adds to the difficulty for newcomers to differentiate themselves. To remain competitive, companies must focus on innovation, whether through new drug formulations, strategic partnerships, or acquisitions.

Key Market Trends

Technological Advancements

Technological progress in healthcare is revolutionizing the development, diagnosis, and treatment of atherosclerosis, which is contributing to the growth of the market. Modern imaging technologies such as CT angiography, MRI, and intravascular ultrasound (IVUS) provide high-resolution images of blood vessels, enabling more accurate assessment of plaque buildup and its severity. Additionally, blood tests that incorporate biomarkers like high-sensitivity C-reactive protein (hs-CRP) and lipoprotein-associated phospholipase A2 (Lp-PLA2) aid in the early detection and risk assessment of atherosclerosis.

Artificial intelligence (AI) and machine learning are also enhancing the diagnosis of atherosclerosis by analyzing medical imaging and patient data to identify patterns and predict disease progression. These advancements are improving both the accuracy and efficiency of diagnosing atherosclerosis, contributing to better patient outcomes.

Key Market Players

• F. Hoffmann-La Roche Ltd
• Novartis AG
• Merck & Co. Inc.
• Pfizer Inc.
• Eli Lilly and Co.
• Sanofi S.A.
• AstraZeneca Plc
• Bayer AG
• Regeneron Pharmaceuticals Inc.
• GSK Plc

Report Scope

This report segments the Global Atherosclerosis Drugs Market into the following categories:

• Diagnosis
• Ankle-brachial Index
• Doppler Ultrasound
• Echocardiogram
• Electrocardiogram
• Blood Tests
• Others
• Treatment
• Medication
• Surgery
• Others
• Route of Administration
• Oral
• Parenteral
• Others
• End User
• Hospitals & Clinics
• Ambulatory Care Centers
• Others
• Region
• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia-Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE

Competitive Landscape

The report includes detailed profiles of major companies in the atherosclerosis drugs market, offering insights into their market strategies and financial performance.

Available Customizations

The Global Atherosclerosis Drugs Market report can be customized to meet specific company needs, including detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validations
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Atherosclerosis Drugs Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Diagnosis (Ankle-brachial Index, Doppler Ultrasound, Echocardiogram, Electrocardiogram, Blood Tests, Others)
  • 5.2.2. By Treatment (Medication, Surgery, Others)
  • 5.2.3. By Route of Administration (Oral, Parenteral, Others)
  • 5.2.4. By End User (Hospitals & Clinics, Ambulatory Care Centers, Others),By Region
  • 5.2.5. By Region
  • 5.2.6. By Company (2024)
• 5.3. Market Map

6. North America Atherosclerosis Drugs Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Diagnosis
  • 6.2.2. By Treatment
  • 6.2.3. By Route of Administration
  • 6.2.4. By End User
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Atherosclerosis Drugs Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Diagnosis
      • 6.3.1.2.2. By Treatment
      • 6.3.1.2.3. By Route of Administration
      • 6.3.1.2.4. By End User
  • 6.3.2. Canada Atherosclerosis Drugs Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Diagnosis
      • 6.3.2.2.2. By Treatment
      • 6.3.2.2.3. By Route of Administration
      • 6.3.2.2.4. By End User
  • 6.3.3. Mexico Atherosclerosis Drugs Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Diagnosis
      • 6.3.3.2.2. By Treatment
      • 6.3.3.2.3. By Route of Administration
      • 6.3.3.2.4. By End User

7. Europe Atherosclerosis Drugs Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Diagnosis
  • 7.2.2. By Treatment
  • 7.2.3. By Route of Administration
  • 7.2.4. By End User
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Atherosclerosis Drugs Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Diagnosis
      • 7.3.1.2.2. By Treatment
      • 7.3.1.2.3. By Route of Administration
      • 7.3.1.2.4. By End User
  • 7.3.2. United Kingdom Atherosclerosis Drugs Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Diagnosis
      • 7.3.2.2.2. By Treatment
      • 7.3.2.2.3. By Route of Administration
      • 7.3.2.2.4. By End User
  • 7.3.3. Italy Atherosclerosis Drugs Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Diagnosis
      • 7.3.3.2.2. By Treatment
      • 7.3.3.2.3. By Route of Administration
      • 7.3.3.2.4. By End User
  • 7.3.4. France Atherosclerosis Drugs Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Diagnosis
      • 7.3.4.2.2. By Treatment
      • 7.3.4.2.3. By Route of Administration
      • 7.3.4.2.4. By End User
  • 7.3.5. Spain Atherosclerosis Drugs Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Diagnosis
      • 7.3.5.2.2. By Treatment
      • 7.3.5.2.3. By Route of Administration
      • 7.3.5.2.4. By End User

8. Asia-Pacific Atherosclerosis Drugs Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Diagnosis
  • 8.2.2. By Treatment
  • 8.2.3. By Route of Administration
  • 8.2.4. By End User
  • 8.2.5. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Atherosclerosis Drugs Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Diagnosis
      • 8.3.1.2.2. By Treatment
      • 8.3.1.2.3. By Route of Administration
      • 8.3.1.2.4. By End User
  • 8.3.2. India Atherosclerosis Drugs Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Diagnosis
      • 8.3.2.2.2. By Treatment
      • 8.3.2.2.3. By Route of Administration
      • 8.3.2.2.4. By End User
  • 8.3.3. Japan Atherosclerosis Drugs Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Diagnosis
      • 8.3.3.2.2. By Treatment
      • 8.3.3.2.3. By Route of Administration
      • 8.3.3.2.4. By End User
  • 8.3.4. South Korea Atherosclerosis Drugs Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Diagnosis
      • 8.3.4.2.2. By Treatment
      • 8.3.4.2.3. By Route of Administration
      • 8.3.4.2.4. By End User
  • 8.3.5. Australia Atherosclerosis Drugs Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Diagnosis
      • 8.3.5.2.2. By Treatment
      • 8.3.5.2.3. By Route of Administration
      • 8.3.5.2.4. By End User

9. South America Atherosclerosis Drugs Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Diagnosis
  • 9.2.2. By Treatment
  • 9.2.3. By Route of Administration
  • 9.2.4. By End User
  • 9.2.5. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Atherosclerosis Drugs Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Diagnosis
      • 9.3.1.2.2. By Treatment
      • 9.3.1.2.3. By Route of Administration
      • 9.3.1.2.4. By End User
  • 9.3.2. Argentina Atherosclerosis Drugs Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Diagnosis
      • 9.3.2.2.2. By Treatment
      • 9.3.2.2.3. By Route of Administration
      • 9.3.2.2.4. By End User
  • 9.3.3. Colombia Atherosclerosis Drugs Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Diagnosis
      • 9.3.3.2.2. By Treatment
      • 9.3.3.2.3. By Route of Administration
      • 9.3.3.2.4. By End User

10. Middle East and Africa Atherosclerosis Drugs Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Diagnosis
  • 10.2.2. By Treatment
  • 10.2.3. By Route of Administration
  • 10.2.4. By End User
  • 10.2.5. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Atherosclerosis Drugs Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Diagnosis
      • 10.3.1.2.2. By Treatment
      • 10.3.1.2.3. By Route of Administration
      • 10.3.1.2.4. By End User
  • 10.3.2. Saudi Arabia Atherosclerosis Drugs Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Diagnosis
      • 10.3.2.2.2. By Treatment
      • 10.3.2.2.3. By Route of Administration
      • 10.3.2.2.4. By End User
  • 10.3.3. UAE Atherosclerosis Drugs Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Diagnosis
      • 10.3.3.2.2. By Treatment
      • 10.3.3.2.3. By Route of Administration
      • 10.3.3.2.4. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Porter's Five Forces Analysis

• 13.1. Competition in the Industry
• 13.2. Potential of New Entrants
• 13.3. Power of Suppliers
• 13.4. Power of Customers
• 13.5. Threat of Substitute Products

14. Competitive Landscape

• 14.1. F. Hoffmann-La Roche Ltd
  • 14.1.1. Business Overview
  • 14.1.2. Company Snapshot
  • 14.1.3. Products & Services
  • 14.1.4. Financials (As Reported)
  • 14.1.5. Recent Developments
  • 14.1.6. Key Personnel Details
  • 14.1.7. SWOT Analysis
• 14.2. Novartis AG
• 14.3. Merck & Co. Inc.
• 14.4. Pfizer Inc.
• 14.5. Eli Lilly and Co.
• 14.6. Sanofi S.A.
• 14.7. AstraZeneca Plc
• 14.8. Bayer AG
• 14.9. Regeneron Pharmaceuticals Inc.
• 14.10. GSK Plc

15. Strategic Recommendations

16. About Us & Disclaimer